Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2020-09-11 Regulatory Filings
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of discernible information and the inability to identify the nature of the document, it cannot be classified into any specific filing category based on the given definitions. According to the fallback rule, documents that do not neatly fit into any category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the most appropriate classification is Regulatory Filings (RNS) with moderate confidence due to the lack of readable content.
2020-09-11 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from legal counsel to the SEC staff regarding comments on a confidential draft Registration Statement on Form S-1 for Praxis Precision Medicines, Inc. It addresses specific SEC comments on the company's disclosures, clinical trial descriptions, financial terms of license agreements, and other regulatory compliance matters related to the S-1 registration process. The presence of references to Form S-1, responses to SEC comment letters, and amendments to the draft registration statement clearly indicate this is a regulatory filing related to a securities registration process, not a financial report, earnings release, or other types of filings. The document is not an announcement of a report but a substantive response to SEC comments, fitting the category of Regulatory Filings (RNS).
2020-08-28 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement confidentially submitted to the SEC, dated August 28, 2020, for Praxis Precision Medicines, Inc. It is a detailed registration statement for an initial public offering (IPO) of common stock, including extensive information such as company overview, risk factors, use of proceeds, capitalization, management discussion and analysis, executive compensation, principal stockholders, underwriting details, and audited financial statements. The presence of a registration statement under the Securities Act of 1933, with detailed financial and business disclosures, is characteristic of a capital raising filing. This type of document is best classified as a Capital/Financing Update (CAP) because it relates to the company's fundraising activities through an IPO. It is not an annual or quarterly report, nor a proxy or governance document, but a registration statement for securities offering.
2020-08-28 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The provided document text appears to be heavily encoded or corrupted, containing mostly non-readable characters and no discernible financial, regulatory, or corporate filing content. There are no clear references to any report titles, fiscal periods, regulatory bodies, or keywords that would indicate a specific filing type. The document length is 15,000 characters, which is substantial, but the content does not contain meaningful text to classify as a financial or corporate report. Given the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS).
2020-08-19 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement confidentially submitted to the SEC, which is a filing used for initial public offerings (IPOs) to register securities for sale to the public. It includes detailed information about the company, its business, risk factors, management, financial data, and underwriting details. This type of filing is related to capital raising and financing activities. It is not an annual report, earnings release, or any other type of report but specifically a registration statement for securities offering under the Securities Act of 1933. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not just an announcement or summary.
2020-07-22 English
Regulatory Filings 2019
Regulatory Filings
2019-06-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.